text_1: Up to 50 percent of women with advanced-stage ovarian cancer could be cured with 1 treatment model
text_2: This news release summarizes a review article published in Nature Reviews Clinical Oncology which assesses the available evidence and makes recommendations concerning the treatment of advanced ovarian cancer. The author of the review argues that adopting a more aggressive standard of treatment for this cancer type that involves locally directed adjuvant chemotherapy could increase cure rates from 20% to 50%. The news release uses some of the language in the review but, unsurprisingly, it appears more optimistic than the perspective piece. The release doesn’t address costs or harms related to such a course of  treatment, nor does it give readers any information about how the original article reached the conclusion that survival rates could be increased up to 50 percent. Exceptional claims require exceptional evidence, and that’s missing here. Ovarian cancer is a dismal disease with a dismal prognosis. More than 90% of women who die from ovarian cancer have been at the advanced stage. The prospect of curing or significantly extending life with advanced cancer is, understandably, exciting and well worth covering. According to the CDC, ovarian cancer is diagnosed in more than 20,000 women in the United States each year and is the fifth leading cause of cancer death among U.S. women.